Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock Iterum Therapeutics (NASDAQ: ITRM ) stock is taking off on Monday as investors react to news of a clinical trial agreement with the U.S. Food and Drug Administration (FDA). This agreemen...
The shares of clinical-stage pharma Iterum Therapeutics ( NASDAQ: ITRM ) jumped ~64% in the morning hours Monday after the company announced an agreement with the FDA over the design of a Phase 3 trial for oral sulopenem, a candidate for urinary tract infections (UTI). ...
Penny Stocks To Buy If you want to make money in the stock market today and do it quickly, penny stocks might be on your watch list. According to the definition, we’re talking about stocks trading below $5. But for some, they look for much cheaper stocks to buy. Penny Stocks ...
--SPA supports protocol for Phase 3 Clinical Trial of Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections-- --Clinical Trial Expected to Begin Enrollment in Q4 2022-- DUBLIN, Ireland and CHICAGO, July 11, 2022 (GLOBE NEWSWIRE) -- Iterum Thera...
Iterum Therapeutics press release (NASDAQ:ITRM): Q1 Non-GAAP EPS of -$0.03 beats by $0.01. Cash, cash equivalents and short-term investments was $75.3 million at March 31, 2022. For further details see: Iterum Therapeutics Non-GAAP EPS of -$0.03 beats by $0.01
-General Alignment with FDA on Key Aspects of Design of Proposed Additional Clinical Trial- -Cash Runway into 2024- DUBLIN, Ireland and CHICAGO, May 13, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (“Iterum”), a clinical-stage pharmaceutical co...
DUBLIN, Ireland and CHICAGO, April 25, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both co...
Iterum Therapeutics plc (ITRM) Q4 2021 Earnings Conference Call March 28, 2022 08:30 AM ET Company Participants Louise Barrett - Senior Vice President of Legal Affairs Corey Fishman - Chief Executive Officer Judy Matthews - Chief Financial Officer Conference Call Participants Thomas Yip - H.C...
Iterum Therapeutics press release (NASDAQ:ITRM): Q4 GAAP EPS of -$0.02 beats by $0.02. Cash, cash equivalents and short-term investments of $81.3M. The company expects that its current cash, cash equivalents and short-term investments will be sufficient to fund its operations into 2024. ...
- -Registration Trial for uUTI Planned in Second Half of 2022- - - -Cash Runway into 2024- - --Company to host conference call today at 8:30am ET-- DUBLIN, Ireland and CHICAGO, March 28, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a...
News, Short Squeeze, Breakout and More Instantly...
Iterum Therapeutics plc Company Name:
ITRM Stock Symbol:
NASDAQ Market:
Iterum Therapeutics plc Website:
A look at the top 10 most actives in the United States Conduit Pharmaceuticals Inc. (CDT) rose 40.0% to $0.3361 on volume of 63,970,490 shares Yoshitsu Co. Ltd (TKLF) rose 64.0% to $0.5024 on volume of 62,618,792 shares Silo Pharma Inc. (SILO) rose 91.8% to $2.0522 on volume of 59,055,593...
DUBLIN, Ireland and CHICAGO, June 21, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community...
DUBLIN and CHICAGO, June 05, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hosp...